Time filter

Source Type

He J.-B.,The First Peoples Hospital of Huaihua City | Yi G.-Z.,The First Peoples Hospital of Huaihua City | Chen Z.-K.,The First Peoples Hospital of Huaihua City | He H.,The First Peoples Hospital of Huaihua City
Journal of Practical Oncology

To observed the inhibition of Suramin on transplanted lung adenocarcinoma in mice by detecting the expression of leptin in transplanted tumor, and to understand the anti-tumor effects of Suramin. Mouse model of transplanted lung adenocarcinoma was built. Twenty-four C57BL/6J mice inoculated with Lewis lung carcinoma were randomly divided into three groups using random number table: control group, cisplatin group and suramin group. After the appropriate drug intervention, mice in each group were sacrificed 24 hours after inoculation. Subcutaneous tumor was peeled off and the inhibitory rate was calculated. The leptin and vascular endothelia growth factor (VEGF) were detected by immunohistochemical methods. The inhibition rate of tumor in cisplatin group and Suramin group was 39.2% and 49.1%, and the tumor weight was significantly different compared with that of control group (P < 0.01), The grayscale values of leptin in control group, cisplatin group and the Suramin group were 135.47 ± 5.30, 127.87 ± 5.51 and 80.44 ± 4.69, VEGF gray values were 156.26 ± 6.45, 134.7± 5.81 and 96.13 ± 5.66. Suramin can significantly inhibit tumor growth in transplated lung adenocarcinoma. The mechanism may be inhibition of leptin and VEGF expression. Source

Discover hidden collaborations